Select a symptom. Pivotal surfaces the peptides most cited for that signal, ranked by clinical fit.
Several million American adults source peptides through research-chemical channels. FDA 503A compounding actions removed BPC-157, CJC-1295, Ipamorelin, MOTS-c, and others from the allowable list between 2020 and 2024, despite decades of international clinical use and no recorded population-level harm signal.
The result: tens of millions self-administering without quality verification, physician context, or recourse. The compounds below are what they are already using. Pivotal is the intelligence layer that should exist between them and the gray market.
This page exists because the alternative is a self-administering public operating from forum posts.
Select a symptom to surface the peptides most often considered for that signal.